This brand name is authorized in Finland, New Zealand
The drug NORFLEX contains one active pharmaceutical ingredient (API):
|
1
Orphenadrine
UNII X0A40N8I4S - ORPHENADRINE CITRATE
|
|
Orphenadrine, which is a congener of diphenhydramine without sharing its soporific effect, is an anti-muscarinic agent. Orphenadrine is used as the hydrochloride in the symptomatic treatment of Parkinsonism. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| M03BC01 | Orphenadrine (citrate) | M Musculo-skeletal system → M03 Muscle relaxants → M03B Muscle relaxants, centrally acting agents → M03BC Ethers, chemically close to antihistamines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 401745, 533158 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 334 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
